Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
for Ovarian Cancer
Sites in Minneapolis +16 more locations
Sponsor: Xencor, Inc.
Sex: All·Age: 15+
Code: NCT06276491·Phase 1·Recruiting·Listed Feb 2024
Oncology Clinical Trials in Minneapolis, MN
As of August 2026, 159 paid clinical trials are recruiting for Oncology in Minneapolis, Minnesota. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Filter results
160 clinical trials for Oncology
·Clear filters· Email me when a new oncology trial opens in Minneapolis, MN.
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
for Non-small Cell Lung Cancer (NSCLC)
Sites in Minneapolis, Rochester +8 more locations
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT06170788·Phase 3·Recruiting·Listed Dec 2023
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
for Non-small Cell Lung Cancer
Sites in Minneapolis +15 more locations
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT06422143·Phase 3·Recruiting·Listed May 2024
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
for Metastatic Prostate Cancer
Sites in Minneapolis +19 more locations
Sponsor: ORIC Pharmaceuticals
Sex: Male·Age: 18+
Code: NCT05413421·Phase 1·Recruiting·Listed Jun 2022
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
for Advanced Solid Tumor
Sites in Minneapolis +10 more locations
Sponsor: Aulos Bioscience, Inc.
Sex: All·Age: 18+
Code: NCT05267626·Phase 1, Phase 2·Recruiting·Listed Mar 2022
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
for Multiple Myeloma
Drug: Daratumumab
Sites in Minneapolis, Rochester +15 more locations
Sponsor: AbbVie
Sex: All·Age: 18+
Code: NCT07095452·Phase 2, Phase 3·Recruiting·Listed Jul 2025
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
for Hematologic Malignancies
Sites in Minneapolis +10 more locations
Sponsor: Pulmotect, Inc.
Sex: All·Age: 18+
Code: NCT06665100·Phase 2·Recruiting·Listed Oct 2024
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
for Metastatic Melanoma
Drug: Lifileucel
Sites in Minneapolis +17 more locations
Sponsor: Iovance Biotherapeutics, Inc.
Sex: All·Age: 18 - 70
Code: NCT05727904·Phase 3·Recruiting·Listed Feb 2023
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
for High-Grade Serous Ovarian Cancer
Drug: Bevacizumab
Sites in Minneapolis +19 more locations
Sponsor: AbbVie
Sex: All·Age: 18+
Code: NCT05005403·Phase 1·Recruiting·Listed Aug 2021
A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
for Advanced Solid Tumor
Sites in Minneapolis +13 more locations
Sponsor: Eikon Therapeutics
Sex: All·Age: 18 - 89
Code: NCT06253130·Phase 1, Phase 2·Recruiting·Listed Feb 2024
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
for Non-Hodgkin Lymphoma
Sites in Minneapolis +9 more locations
Sponsor: Imugene Limited
Sex: All·Age: 18+
Code: NCT03666000·Phase 1·Recruiting·Listed Sep 2018
Blue Light Cystoscopy With Cysview® Registry
for Bladder Cancer
Sites in Minneapolis +20 more locations
Sponsor: Photocure
Sex: All·Age: 18+
Code: NCT02660645·Recruiting·Listed Jan 2016
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
for Ovarian Cancer
Drug: Relacorilant
Sites in Minneapolis +15 more locations
Sponsor: Corcept Therapeutics
Sex: Female·Age: 18+
Code: NCT06906341·Phase 2·Recruiting·Listed Apr 2025
Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
for Metastatic Breast Cancer
Drug: Palazestrant
Sites in Minneapolis +13 more locations
Sponsor: Olema Pharmaceuticals, Inc.
Sex: All·Age: 18+
Code: NCT05508906·Phase 1·Recruiting·Listed Aug 2022
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
for Advanced Solid Tumor
Sites in Minneapolis +13 more locations
Sponsor: Fate Therapeutics
Sex: All·Age: 18+
Code: NCT06241456·Phase 1·Recruiting·Listed Feb 2024
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
for Brain Cancer
Sites in Minneapolis, Rochester +14 more locations
Sponsor: Adela, Inc
Sex: All·Age: 40+·Accepts healthy volunteers
Code: NCT05366881·Recruiting·Listed May 2022
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
for Endometrial Cancer
Sites in Minneapolis +18 more locations
Sponsor: Kartos Therapeutics, Inc.
Sex: Female·Age: 18+
Code: NCT05797831·Phase 2, Phase 3·Recruiting·Listed Apr 2023
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
for NHL
Sites in Minneapolis +8 more locations
Sponsor: Indapta Therapeutics, INC.
Sex: All·Age: 18+
Code: NCT06119685·Phase 1, Phase 2·Recruiting·Listed Nov 2023
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
for Epithelial Ovarian Cancer
Drug: IMNN-001
Sites in Minneapolis +7 more locations
Sponsor: Imunon
Sex: Female·Age: 18+
Code: NCT06915025·Phase 3·Recruiting·Listed Apr 2025
Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
for Cancer
Sites in Minneapolis, Fridley +4 more locations
Sponsor: Helio Genomics
Sex: All·Age: 18+
Code: NCT05181826·Recruiting·Listed Jan 2022
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
for Non-Small Cell Lung Cancer
Sites in Minneapolis +4 more locations
Sponsor: Fate Therapeutics
Sex: All·Age: 18+
Code: NCT07216105·Phase 1·Recruiting·Listed Oct 2025
Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer
for Metastatic Castration-resistant Prostate Cancer
Sites in Minneapolis +5 more locations
Sponsor: Syntrix Biosystems, Inc.
Sex: Male·Age: 18+
Code: NCT06228053·Phase 2·Recruiting·Listed Jan 2024
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
for Solid Tumor, Adult
Sites in Minneapolis +8 more locations
Sponsor: Vivace Therapeutics, Inc
Sex: All·Age: 18+
Code: NCT04665206·Phase 1, Phase 2·Recruiting·Listed Dec 2020
A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer
for Ovarian Cancer Recurrent
Sites in Minneapolis +3 more locations
Sponsor: Outpace Bio, Inc.
Sex: Female·Age: 18+
Code: NCT07030907·Phase 1·Recruiting·Listed Jun 2025
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
for Advanced Solid Tumor
Sites in Minneapolis, Rochester +7 more locations
Sponsor: TORL Biotherapeutics, LLC
Sex: All·Age: 18+
Code: NCT05103683·Phase 1·Recruiting·Listed Nov 2021
A Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors
for Solid Tumors
Sites in Minneapolis +7 more locations
Sponsor: Adcentrx Therapeutics
Sex: All·Age: 18+
Code: NCT06710379·Phase 1·Recruiting·Listed Nov 2024
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
for Hematologic Malignancy
Sites in Minneapolis +4 more locations
Sponsor: Tr1X, Inc.
Sex: All·Age: 18+
Code: NCT06462365·Phase 1·Recruiting·Listed Jun 2024
Fast-Her: Fasting Effects on Breast Cancer Treatment
for Metastatic Breast Cancer
1 location in Minneapolis
Sponsor: University of Minnesota
Sex: All·Age: 18+
Code: NCT07624617·Recruiting·Listed Jun 2026
First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma
for Astrocytoma
1 location in Minneapolis
Sponsor: Masonic Cancer Center, University of Minnesota
Sex: All·Age: 18 - 75
Code: NCT07560865·Phase 1·Recruiting·Listed May 2026
GTB-5550 in Advanced Solid Tumors
for Tri-specific Killer Engager
1 location in Minneapolis
Sponsor: Masonic Cancer Center, University of Minnesota
Sex: All·Age: 18+
Code: NCT07541573·Phase 1·Recruiting·Listed Apr 2026
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
for Chronic Lymphocytic Leukemia
Drug: Sonrotoclax
Sites in Minneapolis, Saint Louis Park +179 more locations
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All·Age: 65+
Code: NCT07321652·Phase 3·Recruiting·Listed Jan 2026
MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
for AML
1 location in Minneapolis
Sponsor: Masonic Cancer Center, University of Minnesota
Sex: All·Age: 2 - 75
Code: NCT07493538·Phase 2·Recruiting·Listed Mar 2026
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
for Lung Non-Small Cell Carcinoma
Sites in Minneapolis, Saint Louis Park +623 more locations
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18+
Code: NCT04267848·Phase 3·Recruiting·Listed Feb 2020
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
for Breast Cancer
Sites in Minneapolis, Saint Louis Park +1098 more locations
Sponsor: NRG Oncology
Sex: Female·Age: 18 - 60
Code: NCT05879926·Phase 3·Recruiting·Listed May 2023
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
for Head and Neck Squamous Cell Carcinoma
Sites in Minneapolis, Saint Louis Park +461 more locations
Sponsor: ECOG-ACRIN Cancer Research Group
Sex: All·Age: 18+
Code: NCT02734537·Phase 2·Recruiting·Listed Apr 2016
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
for Acute Lymphoblastic Leukemia
Sites in Minneapolis, Saint Louis Park +616 more locations
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All·Age: 40 - 75·Accepts healthy volunteers
Code: NCT05334069·Recruiting·Listed Apr 2022
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
for Chronic Lymphocytic Leukemia
Sites in Minneapolis, Saint Louis Park +295 more locations
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18+
Code: NCT04269902·Phase 3·Recruiting·Listed Feb 2020
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
for Fallopian Tube Endometrioid Adenocarcinoma
Drug: Bevacizumab
Sites in Minneapolis, Saint Louis Park +653 more locations
Sponsor: NRG Oncology
Sex: All·Age: 18+
Code: NCT06580314·Phase 3·Recruiting·Listed Aug 2024
Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)
for Malignant Solid Neoplasm
Sites in Minneapolis, Saint Louis Park +353 more locations
Sponsor: ECOG-ACRIN Cancer Research Group
Sex: All·Age: All ages·Accepts healthy volunteers
Code: NCT06295367·Recruiting·Listed Mar 2024
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
for Biochemically Recurrent Prostate Carcinoma
Drug: Apalutamide
Sites in Minneapolis, Saint Louis Park +276 more locations
Sponsor: ECOG-ACRIN Cancer Research Group
Sex: Male·Age: 18+
Code: NCT04423211·Phase 3·Recruiting·Listed Jun 2020
Conditions in Oncology (Minneapolis, MN)
Solid tumor· 24Non-small cell lung cancer (NSCLC)· 20Acute myeloid leukemia (AML)· 18Breast cancer· 17Ovarian cancer· 17Cancer (any)· 13Colorectal cancer· 11Endometrial cancer· 11Hematologic malignancy· 9Metastatic breast cancer· 8Multiple myeloma· 8Myelodysplastic syndromes (MDS)· 8Melanoma· 8Leukemia (other)· 7Non-Hodgkin lymphoma· 7Neuroblastoma· 7Prostate cancer· 6Metastatic prostate cancer· 6Acute lymphoblastic leukemia· 6Head and neck cancer· 6Chronic lymphocytic leukemia (CLL)· 5Lung cancer· 4Pancreatic cancer· 4Cervical cancer· 4Fallopian tube cancer· 4Myelofibrosis· 4Hodgkin lymphoma· 4Small lymphocytic lymphoma· 4Triple-negative breast cancer· 3HER2-negative breast cancer· 3Esophageal cancer· 3Kidney cancer· 3Follicular lymphoma· 3HER2-positive breast cancer· 2Gastroesophageal junction cancer· 2Liver cancer· 2Bladder cancer· 2Glioblastoma· 2Brain cancer· 2Myeloproliferative neoplasm· 2Diffuse large B-cell lymphoma (DLBCL)· 2Marginal zone lymphoma· 2Burkitt lymphoma· 2Thyroid cancer· 2Sarcoma· 2Gastric cancer· 1Brain metastases· 1Mantle cell lymphoma· 1Osteosarcoma· 1Ewing sarcoma· 1Rhabdomyosarcoma· 1Pediatric cancer· 1Mesothelioma· 1